NEW YORK (GenomeWeb News) — George Mason University will combine the "expertise" from two of its research centers to use proteomics and molecular biology along with nanotechnology to hunt for blood-borne markers of infectious disease, the University said yesterday.
Using funding from the US Department of Energy, the school plans to combine expertise from its Center for Applied Proteomics and Molecular Medicine with its National Center for Biodefense and Infectious Diseases to create a Biomedical Research laboratory that GMU said will open in 2009.
NCBID Executive Director Charles Bailey said the collaboration “illustrates how proteomic technologies combined with unique nanotechnology methodology can be used to better understand, diagnose, and treat infectious diseases.”
Bailey said the program initially aims to focus on the bacteria that causes anthrax and tularemia, and hopes to find protein biomarkers that could identify disease onset before a patient becomes symptomatic. The researchers will specifically compare pre-symptomatic and post-symptomatic biomarkers found in the blood.